nodes	percent_of_prediction	percent_of_DWPC	metapath
Indomethacin—UGT2B7—urinary bladder cancer	0.191	0.472	CbGaD
Indomethacin—CXCL8—urinary bladder cancer	0.108	0.267	CbGaD
Indomethacin—PPARG—urinary bladder cancer	0.0747	0.184	CbGaD
Indomethacin—ABCC11—Methotrexate—urinary bladder cancer	0.0324	0.083	CbGbCtD
Indomethacin—PTGS2—urinary bladder cancer	0.0316	0.0778	CbGaD
Indomethacin—ABCC6—Cisplatin—urinary bladder cancer	0.0287	0.0734	CbGbCtD
Indomethacin—ABCC6—Etoposide—urinary bladder cancer	0.0282	0.0722	CbGbCtD
Indomethacin—AKR1C3—Doxorubicin—urinary bladder cancer	0.0256	0.0655	CbGbCtD
Indomethacin—ABCC6—Doxorubicin—urinary bladder cancer	0.0192	0.0492	CbGbCtD
Indomethacin—ABCC3—Fluorouracil—urinary bladder cancer	0.0162	0.0415	CbGbCtD
Indomethacin—UGT2B7—Epirubicin—urinary bladder cancer	0.015	0.0385	CbGbCtD
Indomethacin—ABCC3—Cisplatin—urinary bladder cancer	0.0138	0.0353	CbGbCtD
Indomethacin—ABCC3—Etoposide—urinary bladder cancer	0.0135	0.0347	CbGbCtD
Indomethacin—SLC22A7—Fluorouracil—urinary bladder cancer	0.0127	0.0325	CbGbCtD
Indomethacin—ABCC4—Fluorouracil—urinary bladder cancer	0.0124	0.0317	CbGbCtD
Indomethacin—ABCC1—Epirubicin—urinary bladder cancer	0.0107	0.0273	CbGbCtD
Indomethacin—UGT1A1—Etoposide—urinary bladder cancer	0.0101	0.0259	CbGbCtD
Indomethacin—ABCB1—Mitomycin—urinary bladder cancer	0.00976	0.025	CbGbCtD
Indomethacin—ABCC3—Doxorubicin—urinary bladder cancer	0.00923	0.0236	CbGbCtD
Indomethacin—ABCC3—Methotrexate—urinary bladder cancer	0.00894	0.0229	CbGbCtD
Indomethacin—ABCC1—Etoposide—urinary bladder cancer	0.00831	0.0213	CbGbCtD
Indomethacin—SLC22A11—Methotrexate—urinary bladder cancer	0.00734	0.0188	CbGbCtD
Indomethacin—ABCC2—Carboplatin—urinary bladder cancer	0.00733	0.0188	CbGbCtD
Indomethacin—SLC22A7—Methotrexate—urinary bladder cancer	0.00699	0.0179	CbGbCtD
Indomethacin—ABCC4—Methotrexate—urinary bladder cancer	0.00683	0.0175	CbGbCtD
Indomethacin—ABCC2—Cisplatin—urinary bladder cancer	0.00626	0.016	CbGbCtD
Indomethacin—PTGS2—Cisplatin—urinary bladder cancer	0.00619	0.0158	CbGbCtD
Indomethacin—ABCC2—Etoposide—urinary bladder cancer	0.00615	0.0158	CbGbCtD
Indomethacin—PTGS2—Etoposide—urinary bladder cancer	0.00608	0.0156	CbGbCtD
Indomethacin—ABCC1—Doxorubicin—urinary bladder cancer	0.00567	0.0145	CbGbCtD
Indomethacin—ABCC1—Methotrexate—urinary bladder cancer	0.00549	0.0141	CbGbCtD
Indomethacin—PTGS1—Etoposide—urinary bladder cancer	0.00513	0.0131	CbGbCtD
Indomethacin—SLCO1A2—Methotrexate—urinary bladder cancer	0.0049	0.0126	CbGbCtD
Indomethacin—SLCO1B1—Methotrexate—urinary bladder cancer	0.00463	0.0118	CbGbCtD
Indomethacin—ALB—Fluorouracil—urinary bladder cancer	0.00459	0.0118	CbGbCtD
Indomethacin—SLC22A8—Methotrexate—urinary bladder cancer	0.00427	0.0109	CbGbCtD
Indomethacin—ABCC2—Doxorubicin—urinary bladder cancer	0.0042	0.0107	CbGbCtD
Indomethacin—ABCC2—Methotrexate—urinary bladder cancer	0.00406	0.0104	CbGbCtD
Indomethacin—SLC22A6—Methotrexate—urinary bladder cancer	0.00297	0.00762	CbGbCtD
Indomethacin—ABCB1—Gemcitabine—urinary bladder cancer	0.00281	0.00719	CbGbCtD
Indomethacin—ALB—Methotrexate—urinary bladder cancer	0.00253	0.00649	CbGbCtD
Indomethacin—CYP2C9—Fluorouracil—urinary bladder cancer	0.00248	0.00634	CbGbCtD
Indomethacin—CYP2C9—Cisplatin—urinary bladder cancer	0.0021	0.00539	CbGbCtD
Indomethacin—ABCB1—Cisplatin—urinary bladder cancer	0.00204	0.00523	CbGbCtD
Indomethacin—ABCB1—Etoposide—urinary bladder cancer	0.00201	0.00514	CbGbCtD
Indomethacin—UGT1A1—urine—urinary bladder cancer	0.00171	0.0329	CbGeAlD
Indomethacin—PTGR2—prostate gland—urinary bladder cancer	0.00149	0.0287	CbGeAlD
Indomethacin—ABCB1—Doxorubicin—urinary bladder cancer	0.00137	0.0035	CbGbCtD
Indomethacin—ABCB1—Methotrexate—urinary bladder cancer	0.00132	0.00339	CbGbCtD
Indomethacin—PTGR2—seminal vesicle—urinary bladder cancer	0.00126	0.0243	CbGeAlD
Indomethacin—PTGDR2—female reproductive system—urinary bladder cancer	0.00123	0.0236	CbGeAlD
Indomethacin—SLC22A8—urine—urinary bladder cancer	0.0011	0.0213	CbGeAlD
Indomethacin—PTGR2—renal system—urinary bladder cancer	0.00102	0.0196	CbGeAlD
Indomethacin—PTGR2—urethra—urinary bladder cancer	0.000998	0.0192	CbGeAlD
Indomethacin—CYP2C19—urine—urinary bladder cancer	0.000925	0.0178	CbGeAlD
Indomethacin—GLO1—prostate gland—urinary bladder cancer	0.000921	0.0177	CbGeAlD
Indomethacin—PLA2G2A—prostate gland—urinary bladder cancer	0.000856	0.0165	CbGeAlD
Indomethacin—CXCL8—prostate gland—urinary bladder cancer	0.000847	0.0163	CbGeAlD
Indomethacin—ABCC11—female reproductive system—urinary bladder cancer	0.000805	0.0155	CbGeAlD
Indomethacin—PPARA—prostate gland—urinary bladder cancer	0.0008	0.0154	CbGeAlD
Indomethacin—Naproxen—UGT2B7—urinary bladder cancer	0.000789	0.288	CrCbGaD
Indomethacin—GLO1—seminal vesicle—urinary bladder cancer	0.000779	0.015	CbGeAlD
Indomethacin—ABCC6—Podofilox—Etoposide—urinary bladder cancer	0.000775	0.434	CbGdCrCtD
Indomethacin—SLC10A1—prostate gland—urinary bladder cancer	0.000769	0.0148	CbGeAlD
Indomethacin—PTGR2—vagina—urinary bladder cancer	0.000736	0.0142	CbGeAlD
Indomethacin—PLA2G2A—seminal vesicle—urinary bladder cancer	0.000724	0.014	CbGeAlD
Indomethacin—UGT2B7—prostate gland—urinary bladder cancer	0.00072	0.0139	CbGeAlD
Indomethacin—CYP2C9—urine—urinary bladder cancer	0.000717	0.0138	CbGeAlD
Indomethacin—AKR1C3—Podofilox—Etoposide—urinary bladder cancer	0.000678	0.379	CbGdCrCtD
Indomethacin—GLO1—epithelium—urinary bladder cancer	0.000677	0.013	CbGeAlD
Indomethacin—AKR1C3—prostate gland—urinary bladder cancer	0.000664	0.0128	CbGeAlD
Indomethacin—GLO1—smooth muscle tissue—urinary bladder cancer	0.000652	0.0126	CbGeAlD
Indomethacin—SLC10A1—seminal vesicle—urinary bladder cancer	0.00065	0.0125	CbGeAlD
Indomethacin—PLA2G2A—epithelium—urinary bladder cancer	0.000629	0.0121	CbGeAlD
Indomethacin—GLO1—renal system—urinary bladder cancer	0.000628	0.0121	CbGeAlD
Indomethacin—GLO1—urethra—urinary bladder cancer	0.000616	0.0119	CbGeAlD
Indomethacin—UGT1A1—prostate gland—urinary bladder cancer	0.000613	0.0118	CbGeAlD
Indomethacin—UGT1A9—renal system—urinary bladder cancer	0.000609	0.0117	CbGeAlD
Indomethacin—PLA2G2A—smooth muscle tissue—urinary bladder cancer	0.000606	0.0117	CbGeAlD
Indomethacin—CXCL8—smooth muscle tissue—urinary bladder cancer	0.0006	0.0116	CbGeAlD
Indomethacin—CES1—prostate gland—urinary bladder cancer	0.000593	0.0114	CbGeAlD
Indomethacin—Tolmetin—CXCL8—urinary bladder cancer	0.000592	0.216	CrCbGaD
Indomethacin—PPARA—epithelium—urinary bladder cancer	0.000588	0.0113	CbGeAlD
Indomethacin—PLA2G2A—renal system—urinary bladder cancer	0.000583	0.0112	CbGeAlD
Indomethacin—ABCC6—renal system—urinary bladder cancer	0.000578	0.0111	CbGeAlD
Indomethacin—PLA2G2A—urethra—urinary bladder cancer	0.000573	0.011	CbGeAlD
Indomethacin—CXCL8—urethra—urinary bladder cancer	0.000567	0.0109	CbGeAlD
Indomethacin—PPARA—smooth muscle tissue—urinary bladder cancer	0.000566	0.0109	CbGeAlD
Indomethacin—AKR1C3—seminal vesicle—urinary bladder cancer	0.000562	0.0108	CbGeAlD
Indomethacin—PPARA—renal system—urinary bladder cancer	0.000545	0.0105	CbGeAlD
Indomethacin—SLC10A1—renal system—urinary bladder cancer	0.000524	0.0101	CbGeAlD
Indomethacin—GLO1—female reproductive system—urinary bladder cancer	0.000503	0.00969	CbGeAlD
Indomethacin—UGT2B7—renal system—urinary bladder cancer	0.000491	0.00946	CbGeAlD
Indomethacin—ABCC3—prostate gland—urinary bladder cancer	0.000484	0.00932	CbGeAlD
Indomethacin—SLC22A11—renal system—urinary bladder cancer	0.000479	0.00922	CbGeAlD
Indomethacin—PTGR2—lymph node—urinary bladder cancer	0.000476	0.00917	CbGeAlD
Indomethacin—AKR1C3—smooth muscle tissue—urinary bladder cancer	0.00047	0.00906	CbGeAlD
Indomethacin—PLA2G2A—female reproductive system—urinary bladder cancer	0.000467	0.009	CbGeAlD
Indomethacin—SLC22A7—renal system—urinary bladder cancer	0.000467	0.009	CbGeAlD
Indomethacin—Tolmetin—MPO—urinary bladder cancer	0.000461	0.168	CrCbGaD
Indomethacin—GLO1—vagina—urinary bladder cancer	0.000455	0.00876	CbGeAlD
Indomethacin—AKR1C3—urethra—urinary bladder cancer	0.000445	0.00857	CbGeAlD
Indomethacin—PPARG—prostate gland—urinary bladder cancer	0.00044	0.00847	CbGeAlD
Indomethacin—PPARA—female reproductive system—urinary bladder cancer	0.000436	0.00841	CbGeAlD
Indomethacin—SLC10A1—female reproductive system—urinary bladder cancer	0.00042	0.00809	CbGeAlD
Indomethacin—CXCL8—vagina—urinary bladder cancer	0.000418	0.00806	CbGeAlD
Indomethacin—UGT1A1—renal system—urinary bladder cancer	0.000418	0.00805	CbGeAlD
Indomethacin—ABCC4—prostate gland—urinary bladder cancer	0.000399	0.00769	CbGeAlD
Indomethacin—SLC22A8—prostate gland—urinary bladder cancer	0.000396	0.00763	CbGeAlD
Indomethacin—UGT2B7—female reproductive system—urinary bladder cancer	0.000393	0.00758	CbGeAlD
Indomethacin—ABCC2—prostate gland—urinary bladder cancer	0.000386	0.00745	CbGeAlD
Indomethacin—SLC22A11—female reproductive system—urinary bladder cancer	0.000383	0.00739	CbGeAlD
Indomethacin—SLCO1B1—renal system—urinary bladder cancer	0.000347	0.0067	CbGeAlD
Indomethacin—ABCC1—prostate gland—urinary bladder cancer	0.00034	0.00656	CbGeAlD
Indomethacin—Bezafibrate—PPARG—urinary bladder cancer	0.000337	0.123	CrCbGaD
Indomethacin—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.000333	0.187	CbGdCrCtD
Indomethacin—ABCC3—renal system—urinary bladder cancer	0.00033	0.00635	CbGeAlD
Indomethacin—AKR1C3—vagina—urinary bladder cancer	0.000328	0.00632	CbGeAlD
Indomethacin—CES1—female reproductive system—urinary bladder cancer	0.000324	0.00624	CbGeAlD
Indomethacin—PPARG—epithelium—urinary bladder cancer	0.000323	0.00623	CbGeAlD
Indomethacin—PPARG—smooth muscle tissue—urinary bladder cancer	0.000311	0.006	CbGeAlD
Indomethacin—PPARG—renal system—urinary bladder cancer	0.0003	0.00578	CbGeAlD
Indomethacin—PPARG—urethra—urinary bladder cancer	0.000294	0.00567	CbGeAlD
Indomethacin—GLO1—lymph node—urinary bladder cancer	0.000294	0.00567	CbGeAlD
Indomethacin—ABCC1—seminal vesicle—urinary bladder cancer	0.000288	0.00555	CbGeAlD
Indomethacin—SLCO1A2—renal system—urinary bladder cancer	0.000283	0.00545	CbGeAlD
Indomethacin—SLCO1B1—female reproductive system—urinary bladder cancer	0.000278	0.00536	CbGeAlD
Indomethacin—PLA2G2A—lymph node—urinary bladder cancer	0.000273	0.00527	CbGeAlD
Indomethacin—ABCC4—renal system—urinary bladder cancer	0.000272	0.00524	CbGeAlD
Indomethacin—CXCL8—lymph node—urinary bladder cancer	0.000271	0.00521	CbGeAlD
Indomethacin—SLC22A8—renal system—urinary bladder cancer	0.00027	0.0052	CbGeAlD
Indomethacin—ABCC3—female reproductive system—urinary bladder cancer	0.000264	0.00509	CbGeAlD
Indomethacin—ABCC2—renal system—urinary bladder cancer	0.000263	0.00508	CbGeAlD
Indomethacin—Bromfenac—PTGS2—urinary bladder cancer	0.000257	0.0939	CrCbGaD
Indomethacin—PPARA—lymph node—urinary bladder cancer	0.000255	0.00492	CbGeAlD
Indomethacin—PPARG—female reproductive system—urinary bladder cancer	0.00024	0.00463	CbGeAlD
Indomethacin—PTGS1—prostate gland—urinary bladder cancer	0.000235	0.00453	CbGeAlD
Indomethacin—ABCC1—urethra—urinary bladder cancer	0.000228	0.00439	CbGeAlD
Indomethacin—PTGS2—prostate gland—urinary bladder cancer	0.000225	0.00433	CbGeAlD
Indomethacin—ABCC4—female reproductive system—urinary bladder cancer	0.000218	0.0042	CbGeAlD
Indomethacin—PPARG—vagina—urinary bladder cancer	0.000217	0.00418	CbGeAlD
Indomethacin—AKR1C3—lymph node—urinary bladder cancer	0.000212	0.00409	CbGeAlD
Indomethacin—ABCC2—female reproductive system—urinary bladder cancer	0.000211	0.00407	CbGeAlD
Indomethacin—PTGS1—seminal vesicle—urinary bladder cancer	0.000199	0.00383	CbGeAlD
Indomethacin—PTGS2—seminal vesicle—urinary bladder cancer	0.00019	0.00366	CbGeAlD
Indomethacin—CES1—lymph node—urinary bladder cancer	0.000189	0.00365	CbGeAlD
Indomethacin—Tolmetin—PTGS2—urinary bladder cancer	0.000173	0.0631	CrCbGaD
Indomethacin—PTGS1—epithelium—urinary bladder cancer	0.000173	0.00333	CbGeAlD
Indomethacin—ABCC1—vagina—urinary bladder cancer	0.000168	0.00324	CbGeAlD
Indomethacin—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000166	0.00321	CbGeAlD
Indomethacin—PTGS2—epithelium—urinary bladder cancer	0.000165	0.00318	CbGeAlD
Indomethacin—CYP2C19—vagina—urinary bladder cancer	0.000164	0.00316	CbGeAlD
Indomethacin—PTGS1—renal system—urinary bladder cancer	0.00016	0.00309	CbGeAlD
Indomethacin—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000159	0.00307	CbGeAlD
Indomethacin—ABCC3—lymph node—urinary bladder cancer	0.000154	0.00298	CbGeAlD
Indomethacin—PTGS2—renal system—urinary bladder cancer	0.000153	0.00295	CbGeAlD
Indomethacin—PTGS2—urethra—urinary bladder cancer	0.00015	0.0029	CbGeAlD
Indomethacin—CYP2C9—female reproductive system—urinary bladder cancer	0.000141	0.00271	CbGeAlD
Indomethacin—PPARG—lymph node—urinary bladder cancer	0.00014	0.00271	CbGeAlD
Indomethacin—ABCB1—prostate gland—urinary bladder cancer	0.000139	0.00268	CbGeAlD
Indomethacin—ALB—lymph node—urinary bladder cancer	0.000132	0.00254	CbGeAlD
Indomethacin—Naproxen—PTGS2—urinary bladder cancer	0.00013	0.0475	CrCbGaD
Indomethacin—PTGS1—female reproductive system—urinary bladder cancer	0.000128	0.00247	CbGeAlD
Indomethacin—ABCC4—lymph node—urinary bladder cancer	0.000127	0.00246	CbGeAlD
Indomethacin—ABCC2—lymph node—urinary bladder cancer	0.000123	0.00238	CbGeAlD
Indomethacin—PTGS2—female reproductive system—urinary bladder cancer	0.000123	0.00236	CbGeAlD
Indomethacin—ABCB1—seminal vesicle—urinary bladder cancer	0.000118	0.00227	CbGeAlD
Indomethacin—PTGS1—vagina—urinary bladder cancer	0.000116	0.00224	CbGeAlD
Indomethacin—PTGS2—vagina—urinary bladder cancer	0.000111	0.00214	CbGeAlD
Indomethacin—ABCC1—lymph node—urinary bladder cancer	0.000109	0.00209	CbGeAlD
Indomethacin—ABCB1—epithelium—urinary bladder cancer	0.000102	0.00197	CbGeAlD
Indomethacin—ABCB1—renal system—urinary bladder cancer	9.47e-05	0.00183	CbGeAlD
Indomethacin—ABCB1—urethra—urinary bladder cancer	9.3e-05	0.00179	CbGeAlD
Indomethacin—ABCB1—female reproductive system—urinary bladder cancer	7.59e-05	0.00146	CbGeAlD
Indomethacin—PTGS1—lymph node—urinary bladder cancer	7.51e-05	0.00145	CbGeAlD
Indomethacin—PTGS2—lymph node—urinary bladder cancer	7.17e-05	0.00138	CbGeAlD
Indomethacin—ABCB1—vagina—urinary bladder cancer	6.86e-05	0.00132	CbGeAlD
Indomethacin—Pollakiuria—Epirubicin—urinary bladder cancer	5.75e-05	0.000735	CcSEcCtD
Indomethacin—Body temperature increased—Fluorouracil—urinary bladder cancer	5.75e-05	0.000734	CcSEcCtD
Indomethacin—Sweating—Methotrexate—urinary bladder cancer	5.68e-05	0.000726	CcSEcCtD
Indomethacin—Feeling abnormal—Cisplatin—urinary bladder cancer	5.68e-05	0.000726	CcSEcCtD
Indomethacin—Paraesthesia—Etoposide—urinary bladder cancer	5.67e-05	0.000724	CcSEcCtD
Indomethacin—Weight increased—Epirubicin—urinary bladder cancer	5.66e-05	0.000724	CcSEcCtD
Indomethacin—Haematuria—Methotrexate—urinary bladder cancer	5.65e-05	0.000722	CcSEcCtD
Indomethacin—Dyspnoea—Etoposide—urinary bladder cancer	5.63e-05	0.000719	CcSEcCtD
Indomethacin—Hyperglycaemia—Epirubicin—urinary bladder cancer	5.61e-05	0.000717	CcSEcCtD
Indomethacin—Somnolence—Etoposide—urinary bladder cancer	5.61e-05	0.000717	CcSEcCtD
Indomethacin—Epistaxis—Methotrexate—urinary bladder cancer	5.59e-05	0.000715	CcSEcCtD
Indomethacin—Vomiting—Thiotepa—urinary bladder cancer	5.59e-05	0.000714	CcSEcCtD
Indomethacin—Drowsiness—Epirubicin—urinary bladder cancer	5.55e-05	0.000709	CcSEcCtD
Indomethacin—Rash—Thiotepa—urinary bladder cancer	5.54e-05	0.000708	CcSEcCtD
Indomethacin—Dermatitis—Thiotepa—urinary bladder cancer	5.54e-05	0.000707	CcSEcCtD
Indomethacin—Agranulocytosis—Methotrexate—urinary bladder cancer	5.53e-05	0.000707	CcSEcCtD
Indomethacin—Headache—Thiotepa—urinary bladder cancer	5.51e-05	0.000704	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	5.5e-05	0.000703	CcSEcCtD
Indomethacin—Decreased appetite—Etoposide—urinary bladder cancer	5.49e-05	0.000701	CcSEcCtD
Indomethacin—Pancytopenia—Doxorubicin—urinary bladder cancer	5.47e-05	0.000699	CcSEcCtD
Indomethacin—Renal failure—Epirubicin—urinary bladder cancer	5.45e-05	0.000697	CcSEcCtD
Indomethacin—Body temperature increased—Cisplatin—urinary bladder cancer	5.45e-05	0.000696	CcSEcCtD
Indomethacin—Fatigue—Etoposide—urinary bladder cancer	5.44e-05	0.000695	CcSEcCtD
Indomethacin—Neuropathy peripheral—Epirubicin—urinary bladder cancer	5.44e-05	0.000695	CcSEcCtD
Indomethacin—Stomatitis—Epirubicin—urinary bladder cancer	5.41e-05	0.000691	CcSEcCtD
Indomethacin—Jaundice—Epirubicin—urinary bladder cancer	5.41e-05	0.000691	CcSEcCtD
Indomethacin—Pain—Etoposide—urinary bladder cancer	5.4e-05	0.00069	CcSEcCtD
Indomethacin—Constipation—Etoposide—urinary bladder cancer	5.4e-05	0.00069	CcSEcCtD
Indomethacin—Hypersensitivity—Fluorouracil—urinary bladder cancer	5.35e-05	0.000684	CcSEcCtD
Indomethacin—Haemoglobin—Methotrexate—urinary bladder cancer	5.35e-05	0.000684	CcSEcCtD
Indomethacin—Hepatitis—Methotrexate—urinary bladder cancer	5.32e-05	0.00068	CcSEcCtD
Indomethacin—Haemorrhage—Methotrexate—urinary bladder cancer	5.32e-05	0.00068	CcSEcCtD
Indomethacin—Sweating—Epirubicin—urinary bladder cancer	5.32e-05	0.00068	CcSEcCtD
Indomethacin—Pollakiuria—Doxorubicin—urinary bladder cancer	5.32e-05	0.00068	CcSEcCtD
Indomethacin—Asthenia—Gemcitabine—urinary bladder cancer	5.3e-05	0.000678	CcSEcCtD
Indomethacin—Haematuria—Epirubicin—urinary bladder cancer	5.29e-05	0.000676	CcSEcCtD
Indomethacin—Weight increased—Doxorubicin—urinary bladder cancer	5.24e-05	0.00067	CcSEcCtD
Indomethacin—Epistaxis—Epirubicin—urinary bladder cancer	5.23e-05	0.000669	CcSEcCtD
Indomethacin—Pruritus—Gemcitabine—urinary bladder cancer	5.23e-05	0.000668	CcSEcCtD
Indomethacin—Nausea—Thiotepa—urinary bladder cancer	5.22e-05	0.000667	CcSEcCtD
Indomethacin—Feeling abnormal—Etoposide—urinary bladder cancer	5.2e-05	0.000665	CcSEcCtD
Indomethacin—Hyperglycaemia—Doxorubicin—urinary bladder cancer	5.19e-05	0.000664	CcSEcCtD
Indomethacin—Agranulocytosis—Epirubicin—urinary bladder cancer	5.18e-05	0.000662	CcSEcCtD
Indomethacin—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.16e-05	0.00066	CcSEcCtD
Indomethacin—Pruritus—Fluorouracil—urinary bladder cancer	5.14e-05	0.000657	CcSEcCtD
Indomethacin—Drowsiness—Doxorubicin—urinary bladder cancer	5.13e-05	0.000656	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	5.09e-05	0.00065	CcSEcCtD
Indomethacin—Hypersensitivity—Cisplatin—urinary bladder cancer	5.08e-05	0.000649	CcSEcCtD
Indomethacin—Bradycardia—Epirubicin—urinary bladder cancer	5.07e-05	0.000648	CcSEcCtD
Indomethacin—Diarrhoea—Gemcitabine—urinary bladder cancer	5.06e-05	0.000646	CcSEcCtD
Indomethacin—Renal failure—Doxorubicin—urinary bladder cancer	5.05e-05	0.000645	CcSEcCtD
Indomethacin—Erythema multiforme—Methotrexate—urinary bladder cancer	5.03e-05	0.000643	CcSEcCtD
Indomethacin—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	5.03e-05	0.000643	CcSEcCtD
Indomethacin—Urticaria—Etoposide—urinary bladder cancer	5.01e-05	0.000641	CcSEcCtD
Indomethacin—Haemoglobin—Epirubicin—urinary bladder cancer	5.01e-05	0.00064	CcSEcCtD
Indomethacin—Jaundice—Doxorubicin—urinary bladder cancer	5e-05	0.000639	CcSEcCtD
Indomethacin—Stomatitis—Doxorubicin—urinary bladder cancer	5e-05	0.000639	CcSEcCtD
Indomethacin—Abdominal pain—Etoposide—urinary bladder cancer	4.99e-05	0.000638	CcSEcCtD
Indomethacin—Body temperature increased—Etoposide—urinary bladder cancer	4.99e-05	0.000638	CcSEcCtD
Indomethacin—Hepatitis—Epirubicin—urinary bladder cancer	4.98e-05	0.000636	CcSEcCtD
Indomethacin—Haemorrhage—Epirubicin—urinary bladder cancer	4.98e-05	0.000636	CcSEcCtD
Indomethacin—Diarrhoea—Fluorouracil—urinary bladder cancer	4.97e-05	0.000636	CcSEcCtD
Indomethacin—Tinnitus—Methotrexate—urinary bladder cancer	4.96e-05	0.000634	CcSEcCtD
Indomethacin—Asthenia—Cisplatin—urinary bladder cancer	4.94e-05	0.000632	CcSEcCtD
Indomethacin—Sweating—Doxorubicin—urinary bladder cancer	4.92e-05	0.000629	CcSEcCtD
Indomethacin—Haematuria—Doxorubicin—urinary bladder cancer	4.89e-05	0.000625	CcSEcCtD
Indomethacin—Epistaxis—Doxorubicin—urinary bladder cancer	4.84e-05	0.000619	CcSEcCtD
Indomethacin—Dizziness—Fluorouracil—urinary bladder cancer	4.81e-05	0.000614	CcSEcCtD
Indomethacin—Agranulocytosis—Doxorubicin—urinary bladder cancer	4.79e-05	0.000612	CcSEcCtD
Indomethacin—Diarrhoea—Cisplatin—urinary bladder cancer	4.71e-05	0.000602	CcSEcCtD
Indomethacin—Erythema multiforme—Epirubicin—urinary bladder cancer	4.71e-05	0.000602	CcSEcCtD
Indomethacin—Alopecia—Methotrexate—urinary bladder cancer	4.7e-05	0.000601	CcSEcCtD
Indomethacin—Vomiting—Gemcitabine—urinary bladder cancer	4.7e-05	0.000601	CcSEcCtD
Indomethacin—Bradycardia—Doxorubicin—urinary bladder cancer	4.69e-05	0.0006	CcSEcCtD
Indomethacin—Rash—Gemcitabine—urinary bladder cancer	4.66e-05	0.000596	CcSEcCtD
Indomethacin—Dermatitis—Gemcitabine—urinary bladder cancer	4.66e-05	0.000595	CcSEcCtD
Indomethacin—Hypersensitivity—Etoposide—urinary bladder cancer	4.65e-05	0.000594	CcSEcCtD
Indomethacin—Tinnitus—Epirubicin—urinary bladder cancer	4.64e-05	0.000593	CcSEcCtD
Indomethacin—Erythema—Methotrexate—urinary bladder cancer	4.63e-05	0.000592	CcSEcCtD
Indomethacin—Haemoglobin—Doxorubicin—urinary bladder cancer	4.63e-05	0.000592	CcSEcCtD
Indomethacin—Headache—Gemcitabine—urinary bladder cancer	4.63e-05	0.000592	CcSEcCtD
Indomethacin—Flushing—Epirubicin—urinary bladder cancer	4.62e-05	0.000591	CcSEcCtD
Indomethacin—Vomiting—Fluorouracil—urinary bladder cancer	4.62e-05	0.000591	CcSEcCtD
Indomethacin—Haemorrhage—Doxorubicin—urinary bladder cancer	4.61e-05	0.000589	CcSEcCtD
Indomethacin—Hepatitis—Doxorubicin—urinary bladder cancer	4.61e-05	0.000589	CcSEcCtD
Indomethacin—Rash—Fluorouracil—urinary bladder cancer	4.58e-05	0.000586	CcSEcCtD
Indomethacin—Dermatitis—Fluorouracil—urinary bladder cancer	4.58e-05	0.000585	CcSEcCtD
Indomethacin—Headache—Fluorouracil—urinary bladder cancer	4.55e-05	0.000582	CcSEcCtD
Indomethacin—Asthenia—Etoposide—urinary bladder cancer	4.53e-05	0.000579	CcSEcCtD
Indomethacin—Pruritus—Etoposide—urinary bladder cancer	4.47e-05	0.000571	CcSEcCtD
Indomethacin—Arrhythmia—Epirubicin—urinary bladder cancer	4.45e-05	0.000569	CcSEcCtD
Indomethacin—ABCB1—lymph node—urinary bladder cancer	4.44e-05	0.000855	CbGeAlD
Indomethacin—Alopecia—Epirubicin—urinary bladder cancer	4.4e-05	0.000562	CcSEcCtD
Indomethacin—Nausea—Gemcitabine—urinary bladder cancer	4.39e-05	0.000561	CcSEcCtD
Indomethacin—Vomiting—Cisplatin—urinary bladder cancer	4.38e-05	0.00056	CcSEcCtD
Indomethacin—Vision blurred—Methotrexate—urinary bladder cancer	4.37e-05	0.000558	CcSEcCtD
Indomethacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.36e-05	0.000557	CcSEcCtD
Indomethacin—Rash—Cisplatin—urinary bladder cancer	4.34e-05	0.000555	CcSEcCtD
Indomethacin—Dermatitis—Cisplatin—urinary bladder cancer	4.34e-05	0.000555	CcSEcCtD
Indomethacin—Erythema—Epirubicin—urinary bladder cancer	4.34e-05	0.000554	CcSEcCtD
Indomethacin—Diarrhoea—Etoposide—urinary bladder cancer	4.32e-05	0.000552	CcSEcCtD
Indomethacin—Nausea—Fluorouracil—urinary bladder cancer	4.32e-05	0.000552	CcSEcCtD
Indomethacin—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.3e-05	0.000549	CcSEcCtD
Indomethacin—Tinnitus—Doxorubicin—urinary bladder cancer	4.3e-05	0.000549	CcSEcCtD
Indomethacin—Anaemia—Methotrexate—urinary bladder cancer	4.28e-05	0.000547	CcSEcCtD
Indomethacin—Flushing—Doxorubicin—urinary bladder cancer	4.28e-05	0.000547	CcSEcCtD
Indomethacin—Flatulence—Epirubicin—urinary bladder cancer	4.27e-05	0.000546	CcSEcCtD
Indomethacin—Tension—Epirubicin—urinary bladder cancer	4.25e-05	0.000544	CcSEcCtD
Indomethacin—Nervousness—Epirubicin—urinary bladder cancer	4.21e-05	0.000538	CcSEcCtD
Indomethacin—Malaise—Methotrexate—urinary bladder cancer	4.18e-05	0.000534	CcSEcCtD
Indomethacin—Dizziness—Etoposide—urinary bladder cancer	4.17e-05	0.000533	CcSEcCtD
Indomethacin—Vertigo—Methotrexate—urinary bladder cancer	4.16e-05	0.000532	CcSEcCtD
Indomethacin—Leukopenia—Methotrexate—urinary bladder cancer	4.15e-05	0.00053	CcSEcCtD
Indomethacin—Arrhythmia—Doxorubicin—urinary bladder cancer	4.12e-05	0.000526	CcSEcCtD
Indomethacin—Nausea—Cisplatin—urinary bladder cancer	4.09e-05	0.000523	CcSEcCtD
Indomethacin—Vision blurred—Epirubicin—urinary bladder cancer	4.09e-05	0.000522	CcSEcCtD
Indomethacin—Alopecia—Doxorubicin—urinary bladder cancer	4.07e-05	0.00052	CcSEcCtD
Indomethacin—Ill-defined disorder—Epirubicin—urinary bladder cancer	4.02e-05	0.000514	CcSEcCtD
Indomethacin—Convulsion—Methotrexate—urinary bladder cancer	4.01e-05	0.000513	CcSEcCtD
Indomethacin—Vomiting—Etoposide—urinary bladder cancer	4.01e-05	0.000513	CcSEcCtD
Indomethacin—Erythema—Doxorubicin—urinary bladder cancer	4.01e-05	0.000513	CcSEcCtD
Indomethacin—Anaemia—Epirubicin—urinary bladder cancer	4.01e-05	0.000512	CcSEcCtD
Indomethacin—Rash—Etoposide—urinary bladder cancer	3.98e-05	0.000509	CcSEcCtD
Indomethacin—Dermatitis—Etoposide—urinary bladder cancer	3.98e-05	0.000508	CcSEcCtD
Indomethacin—Headache—Etoposide—urinary bladder cancer	3.95e-05	0.000505	CcSEcCtD
Indomethacin—Flatulence—Doxorubicin—urinary bladder cancer	3.95e-05	0.000505	CcSEcCtD
Indomethacin—Chest pain—Methotrexate—urinary bladder cancer	3.94e-05	0.000504	CcSEcCtD
Indomethacin—Tension—Doxorubicin—urinary bladder cancer	3.94e-05	0.000503	CcSEcCtD
Indomethacin—Malaise—Epirubicin—urinary bladder cancer	3.91e-05	0.0005	CcSEcCtD
Indomethacin—Discomfort—Methotrexate—urinary bladder cancer	3.9e-05	0.000498	CcSEcCtD
Indomethacin—Nervousness—Doxorubicin—urinary bladder cancer	3.9e-05	0.000498	CcSEcCtD
Indomethacin—Vertigo—Epirubicin—urinary bladder cancer	3.9e-05	0.000498	CcSEcCtD
Indomethacin—Syncope—Epirubicin—urinary bladder cancer	3.89e-05	0.000497	CcSEcCtD
Indomethacin—Leukopenia—Epirubicin—urinary bladder cancer	3.88e-05	0.000496	CcSEcCtD
Indomethacin—Palpitations—Epirubicin—urinary bladder cancer	3.83e-05	0.00049	CcSEcCtD
Indomethacin—Confusional state—Methotrexate—urinary bladder cancer	3.81e-05	0.000487	CcSEcCtD
Indomethacin—Loss of consciousness—Epirubicin—urinary bladder cancer	3.81e-05	0.000487	CcSEcCtD
Indomethacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.78e-05	0.000483	CcSEcCtD
Indomethacin—Vision blurred—Doxorubicin—urinary bladder cancer	3.78e-05	0.000483	CcSEcCtD
Indomethacin—Convulsion—Epirubicin—urinary bladder cancer	3.76e-05	0.00048	CcSEcCtD
Indomethacin—Nausea—Etoposide—urinary bladder cancer	3.75e-05	0.000479	CcSEcCtD
Indomethacin—Hypertension—Epirubicin—urinary bladder cancer	3.74e-05	0.000478	CcSEcCtD
Indomethacin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.72e-05	0.000476	CcSEcCtD
Indomethacin—Anaemia—Doxorubicin—urinary bladder cancer	3.71e-05	0.000474	CcSEcCtD
Indomethacin—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.7e-05	0.000473	CcSEcCtD
Indomethacin—Chest pain—Epirubicin—urinary bladder cancer	3.69e-05	0.000472	CcSEcCtD
Indomethacin—Anxiety—Epirubicin—urinary bladder cancer	3.68e-05	0.00047	CcSEcCtD
Indomethacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.66e-05	0.000467	CcSEcCtD
Indomethacin—Discomfort—Epirubicin—urinary bladder cancer	3.65e-05	0.000466	CcSEcCtD
Indomethacin—Malaise—Doxorubicin—urinary bladder cancer	3.62e-05	0.000462	CcSEcCtD
Indomethacin—Vertigo—Doxorubicin—urinary bladder cancer	3.6e-05	0.000461	CcSEcCtD
Indomethacin—Anorexia—Methotrexate—urinary bladder cancer	3.6e-05	0.000461	CcSEcCtD
Indomethacin—Syncope—Doxorubicin—urinary bladder cancer	3.6e-05	0.00046	CcSEcCtD
Indomethacin—Leukopenia—Doxorubicin—urinary bladder cancer	3.59e-05	0.000459	CcSEcCtD
Indomethacin—Confusional state—Epirubicin—urinary bladder cancer	3.57e-05	0.000456	CcSEcCtD
Indomethacin—Palpitations—Doxorubicin—urinary bladder cancer	3.55e-05	0.000453	CcSEcCtD
Indomethacin—Oedema—Epirubicin—urinary bladder cancer	3.54e-05	0.000452	CcSEcCtD
Indomethacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.54e-05	0.000452	CcSEcCtD
Indomethacin—Hypotension—Methotrexate—urinary bladder cancer	3.53e-05	0.000451	CcSEcCtD
Indomethacin—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.53e-05	0.000451	CcSEcCtD
Indomethacin—Shock—Epirubicin—urinary bladder cancer	3.48e-05	0.000445	CcSEcCtD
Indomethacin—Convulsion—Doxorubicin—urinary bladder cancer	3.48e-05	0.000444	CcSEcCtD
Indomethacin—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.46e-05	0.000443	CcSEcCtD
Indomethacin—Hypertension—Doxorubicin—urinary bladder cancer	3.46e-05	0.000443	CcSEcCtD
Indomethacin—Tachycardia—Epirubicin—urinary bladder cancer	3.45e-05	0.000441	CcSEcCtD
Indomethacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.42e-05	0.000437	CcSEcCtD
Indomethacin—Insomnia—Methotrexate—urinary bladder cancer	3.42e-05	0.000437	CcSEcCtD
Indomethacin—Chest pain—Doxorubicin—urinary bladder cancer	3.42e-05	0.000436	CcSEcCtD
Indomethacin—Anxiety—Doxorubicin—urinary bladder cancer	3.4e-05	0.000435	CcSEcCtD
Indomethacin—Paraesthesia—Methotrexate—urinary bladder cancer	3.4e-05	0.000434	CcSEcCtD
Indomethacin—Discomfort—Doxorubicin—urinary bladder cancer	3.37e-05	0.000431	CcSEcCtD
Indomethacin—Anorexia—Epirubicin—urinary bladder cancer	3.37e-05	0.000431	CcSEcCtD
Indomethacin—Dyspnoea—Methotrexate—urinary bladder cancer	3.37e-05	0.000431	CcSEcCtD
Indomethacin—Somnolence—Methotrexate—urinary bladder cancer	3.36e-05	0.00043	CcSEcCtD
Indomethacin—Dyspepsia—Methotrexate—urinary bladder cancer	3.33e-05	0.000425	CcSEcCtD
Indomethacin—Hypotension—Epirubicin—urinary bladder cancer	3.31e-05	0.000423	CcSEcCtD
Indomethacin—Confusional state—Doxorubicin—urinary bladder cancer	3.3e-05	0.000422	CcSEcCtD
Indomethacin—Decreased appetite—Methotrexate—urinary bladder cancer	3.29e-05	0.00042	CcSEcCtD
Indomethacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.27e-05	0.000418	CcSEcCtD
Indomethacin—Oedema—Doxorubicin—urinary bladder cancer	3.27e-05	0.000418	CcSEcCtD
Indomethacin—Fatigue—Methotrexate—urinary bladder cancer	3.26e-05	0.000417	CcSEcCtD
Indomethacin—Pain—Methotrexate—urinary bladder cancer	3.23e-05	0.000413	CcSEcCtD
Indomethacin—Shock—Doxorubicin—urinary bladder cancer	3.22e-05	0.000412	CcSEcCtD
Indomethacin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.21e-05	0.00041	CcSEcCtD
Indomethacin—Insomnia—Epirubicin—urinary bladder cancer	3.2e-05	0.000409	CcSEcCtD
Indomethacin—Tachycardia—Doxorubicin—urinary bladder cancer	3.2e-05	0.000408	CcSEcCtD
Indomethacin—Paraesthesia—Epirubicin—urinary bladder cancer	3.18e-05	0.000406	CcSEcCtD
Indomethacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.17e-05	0.000404	CcSEcCtD
Indomethacin—Dyspnoea—Epirubicin—urinary bladder cancer	3.15e-05	0.000403	CcSEcCtD
Indomethacin—Somnolence—Epirubicin—urinary bladder cancer	3.15e-05	0.000402	CcSEcCtD
Indomethacin—Anorexia—Doxorubicin—urinary bladder cancer	3.12e-05	0.000399	CcSEcCtD
Indomethacin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.12e-05	0.000398	CcSEcCtD
Indomethacin—Dyspepsia—Epirubicin—urinary bladder cancer	3.11e-05	0.000398	CcSEcCtD
Indomethacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.09e-05	0.000395	CcSEcCtD
Indomethacin—Decreased appetite—Epirubicin—urinary bladder cancer	3.08e-05	0.000393	CcSEcCtD
Indomethacin—Hypotension—Doxorubicin—urinary bladder cancer	3.06e-05	0.000391	CcSEcCtD
Indomethacin—Fatigue—Epirubicin—urinary bladder cancer	3.05e-05	0.00039	CcSEcCtD
Indomethacin—Constipation—Epirubicin—urinary bladder cancer	3.03e-05	0.000387	CcSEcCtD
Indomethacin—Pain—Epirubicin—urinary bladder cancer	3.03e-05	0.000387	CcSEcCtD
Indomethacin—Urticaria—Methotrexate—urinary bladder cancer	3e-05	0.000384	CcSEcCtD
Indomethacin—Abdominal pain—Methotrexate—urinary bladder cancer	2.99e-05	0.000382	CcSEcCtD
Indomethacin—Body temperature increased—Methotrexate—urinary bladder cancer	2.99e-05	0.000382	CcSEcCtD
Indomethacin—Insomnia—Doxorubicin—urinary bladder cancer	2.96e-05	0.000378	CcSEcCtD
Indomethacin—Paraesthesia—Doxorubicin—urinary bladder cancer	2.94e-05	0.000376	CcSEcCtD
Indomethacin—Dyspnoea—Doxorubicin—urinary bladder cancer	2.92e-05	0.000373	CcSEcCtD
Indomethacin—Feeling abnormal—Epirubicin—urinary bladder cancer	2.92e-05	0.000373	CcSEcCtD
Indomethacin—Somnolence—Doxorubicin—urinary bladder cancer	2.91e-05	0.000372	CcSEcCtD
Indomethacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.89e-05	0.00037	CcSEcCtD
Indomethacin—Dyspepsia—Doxorubicin—urinary bladder cancer	2.88e-05	0.000368	CcSEcCtD
Indomethacin—Decreased appetite—Doxorubicin—urinary bladder cancer	2.85e-05	0.000364	CcSEcCtD
Indomethacin—Fatigue—Doxorubicin—urinary bladder cancer	2.82e-05	0.000361	CcSEcCtD
Indomethacin—Urticaria—Epirubicin—urinary bladder cancer	2.81e-05	0.000359	CcSEcCtD
Indomethacin—Constipation—Doxorubicin—urinary bladder cancer	2.8e-05	0.000358	CcSEcCtD
Indomethacin—Pain—Doxorubicin—urinary bladder cancer	2.8e-05	0.000358	CcSEcCtD
Indomethacin—Abdominal pain—Epirubicin—urinary bladder cancer	2.8e-05	0.000357	CcSEcCtD
Indomethacin—Body temperature increased—Epirubicin—urinary bladder cancer	2.8e-05	0.000357	CcSEcCtD
Indomethacin—Hypersensitivity—Methotrexate—urinary bladder cancer	2.79e-05	0.000356	CcSEcCtD
Indomethacin—Asthenia—Methotrexate—urinary bladder cancer	2.71e-05	0.000347	CcSEcCtD
Indomethacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.7e-05	0.000345	CcSEcCtD
Indomethacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.68e-05	0.000342	CcSEcCtD
Indomethacin—Pruritus—Methotrexate—urinary bladder cancer	2.68e-05	0.000342	CcSEcCtD
Indomethacin—Hypersensitivity—Epirubicin—urinary bladder cancer	2.61e-05	0.000333	CcSEcCtD
Indomethacin—Urticaria—Doxorubicin—urinary bladder cancer	2.6e-05	0.000332	CcSEcCtD
Indomethacin—Body temperature increased—Doxorubicin—urinary bladder cancer	2.59e-05	0.000331	CcSEcCtD
Indomethacin—Abdominal pain—Doxorubicin—urinary bladder cancer	2.59e-05	0.000331	CcSEcCtD
Indomethacin—Diarrhoea—Methotrexate—urinary bladder cancer	2.59e-05	0.000331	CcSEcCtD
Indomethacin—Asthenia—Epirubicin—urinary bladder cancer	2.54e-05	0.000324	CcSEcCtD
Indomethacin—Pruritus—Epirubicin—urinary bladder cancer	2.5e-05	0.00032	CcSEcCtD
Indomethacin—Dizziness—Methotrexate—urinary bladder cancer	2.5e-05	0.00032	CcSEcCtD
Indomethacin—Diarrhoea—Epirubicin—urinary bladder cancer	2.42e-05	0.000309	CcSEcCtD
Indomethacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.41e-05	0.000308	CcSEcCtD
Indomethacin—Vomiting—Methotrexate—urinary bladder cancer	2.4e-05	0.000307	CcSEcCtD
Indomethacin—Rash—Methotrexate—urinary bladder cancer	2.38e-05	0.000305	CcSEcCtD
Indomethacin—Dermatitis—Methotrexate—urinary bladder cancer	2.38e-05	0.000304	CcSEcCtD
Indomethacin—Headache—Methotrexate—urinary bladder cancer	2.37e-05	0.000303	CcSEcCtD
Indomethacin—Asthenia—Doxorubicin—urinary bladder cancer	2.35e-05	0.0003	CcSEcCtD
Indomethacin—Dizziness—Epirubicin—urinary bladder cancer	2.34e-05	0.000299	CcSEcCtD
Indomethacin—Pruritus—Doxorubicin—urinary bladder cancer	2.32e-05	0.000296	CcSEcCtD
Indomethacin—Vomiting—Epirubicin—urinary bladder cancer	2.25e-05	0.000287	CcSEcCtD
Indomethacin—Nausea—Methotrexate—urinary bladder cancer	2.25e-05	0.000287	CcSEcCtD
Indomethacin—Diarrhoea—Doxorubicin—urinary bladder cancer	2.24e-05	0.000286	CcSEcCtD
Indomethacin—Rash—Epirubicin—urinary bladder cancer	2.23e-05	0.000285	CcSEcCtD
Indomethacin—Dermatitis—Epirubicin—urinary bladder cancer	2.23e-05	0.000285	CcSEcCtD
Indomethacin—Headache—Epirubicin—urinary bladder cancer	2.22e-05	0.000283	CcSEcCtD
Indomethacin—Dizziness—Doxorubicin—urinary bladder cancer	2.17e-05	0.000277	CcSEcCtD
Indomethacin—Nausea—Epirubicin—urinary bladder cancer	2.1e-05	0.000269	CcSEcCtD
Indomethacin—Vomiting—Doxorubicin—urinary bladder cancer	2.08e-05	0.000266	CcSEcCtD
Indomethacin—Rash—Doxorubicin—urinary bladder cancer	2.06e-05	0.000264	CcSEcCtD
Indomethacin—Dermatitis—Doxorubicin—urinary bladder cancer	2.06e-05	0.000264	CcSEcCtD
Indomethacin—Headache—Doxorubicin—urinary bladder cancer	2.05e-05	0.000262	CcSEcCtD
Indomethacin—Nausea—Doxorubicin—urinary bladder cancer	1.94e-05	0.000249	CcSEcCtD
Indomethacin—ABCC1—Disease—FGFR3—urinary bladder cancer	4.15e-06	6.02e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—NAT2—urinary bladder cancer	4.14e-06	6e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	4.14e-06	5.99e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—GPX1—urinary bladder cancer	4.12e-06	5.97e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.11e-06	5.95e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—PTEN—urinary bladder cancer	4.11e-06	5.95e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	4.09e-06	5.92e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	4.09e-06	5.92e-05	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—HRAS—urinary bladder cancer	4.09e-06	5.92e-05	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—PTGS2—urinary bladder cancer	4.08e-06	5.91e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—RRM2—urinary bladder cancer	4.08e-06	5.91e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—MYC—urinary bladder cancer	4.08e-06	5.9e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—ERCC2—urinary bladder cancer	4.04e-06	5.86e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—ERBB2—urinary bladder cancer	4.03e-06	5.83e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.01e-06	5.81e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—EGFR—urinary bladder cancer	3.99e-06	5.77e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—CREBBP—urinary bladder cancer	3.97e-06	5.74e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—GSTP1—urinary bladder cancer	3.96e-06	5.73e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	3.94e-06	5.71e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	3.94e-06	5.71e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—PPARG—urinary bladder cancer	3.93e-06	5.7e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—PPARG—urinary bladder cancer	3.93e-06	5.7e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—EP300—urinary bladder cancer	3.92e-06	5.67e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—IGF1—urinary bladder cancer	3.92e-06	5.67e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	3.91e-06	5.67e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.87e-06	5.61e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	3.84e-06	5.57e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.83e-06	5.55e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CXCL8—urinary bladder cancer	3.82e-06	5.53e-05	CbGpPWpGaD
Indomethacin—PPARA—Gene Expression—MYC—urinary bladder cancer	3.81e-06	5.51e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—MTHFR—urinary bladder cancer	3.8e-06	5.51e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CREBBP—urinary bladder cancer	3.79e-06	5.49e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—HPGDS—urinary bladder cancer	3.78e-06	5.48e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—ENO2—urinary bladder cancer	3.78e-06	5.48e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—CREBBP—urinary bladder cancer	3.78e-06	5.47e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	3.78e-06	5.47e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—NQO1—urinary bladder cancer	3.77e-06	5.46e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—KRAS—urinary bladder cancer	3.77e-06	5.45e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.76e-06	5.44e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—IGF1—urinary bladder cancer	3.75e-06	5.43e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—EGFR—urinary bladder cancer	3.73e-06	5.4e-05	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.69e-06	5.35e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—TYMS—urinary bladder cancer	3.68e-06	5.33e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GSTT1—urinary bladder cancer	3.67e-06	5.31e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.66e-06	5.31e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—IL2—urinary bladder cancer	3.65e-06	5.29e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—NCOR1—urinary bladder cancer	3.64e-06	5.27e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—GSTM1—urinary bladder cancer	3.64e-06	5.27e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	3.61e-06	5.23e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.61e-06	5.23e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—RHOA—urinary bladder cancer	3.59e-06	5.2e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.58e-06	5.18e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—CREBBP—urinary bladder cancer	3.57e-06	5.18e-05	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—PTEN—urinary bladder cancer	3.56e-06	5.16e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CCND1—urinary bladder cancer	3.56e-06	5.15e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—CREBBP—urinary bladder cancer	3.54e-06	5.12e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—KRAS—urinary bladder cancer	3.52e-06	5.1e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—GPX1—urinary bladder cancer	3.48e-06	5.04e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—MMP9—urinary bladder cancer	3.45e-06	5e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—NCOR1—urinary bladder cancer	3.45e-06	4.99e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CDKN1A—urinary bladder cancer	3.44e-06	4.99e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—PTEN—urinary bladder cancer	3.43e-06	4.97e-05	CbGpPWpGaD
Indomethacin—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.43e-06	4.97e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—RHOA—urinary bladder cancer	3.43e-06	4.97e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	3.43e-06	4.96e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—ERCC2—urinary bladder cancer	3.42e-06	4.95e-05	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—EP300—urinary bladder cancer	3.4e-06	4.92e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.39e-06	4.92e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.39e-06	4.92e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.37e-06	4.89e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.34e-06	4.84e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.31e-06	4.8e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.31e-06	4.8e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.29e-06	4.77e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	3.29e-06	4.77e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—EP300—urinary bladder cancer	3.28e-06	4.74e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.24e-06	4.69e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—ERCC2—urinary bladder cancer	3.24e-06	4.69e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—MTHFR—urinary bladder cancer	3.21e-06	4.65e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.21e-06	4.65e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—HRAS—urinary bladder cancer	3.2e-06	4.64e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—RHOA—urinary bladder cancer	3.2e-06	4.63e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—PPARG—urinary bladder cancer	3.2e-06	4.63e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—PPARG—urinary bladder cancer	3.2e-06	4.63e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.19e-06	4.62e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—SRC—urinary bladder cancer	3.19e-06	4.61e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—ERBB2—urinary bladder cancer	3.18e-06	4.6e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—GSTP1—urinary bladder cancer	3.14e-06	4.55e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—PTGS2—urinary bladder cancer	3.09e-06	4.48e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	3.09e-06	4.48e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.09e-06	4.48e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.09e-06	4.48e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—PPARG—urinary bladder cancer	3.08e-06	4.46e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.08e-06	4.46e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	3.07e-06	4.45e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	3.07e-06	4.45e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—NQO1—urinary bladder cancer	3.05e-06	4.41e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—MTHFR—urinary bladder cancer	3.05e-06	4.41e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.04e-06	4.4e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—TERT—urinary bladder cancer	3.04e-06	4.4e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—IL2—urinary bladder cancer	3.01e-06	4.36e-05	CbGpPWpGaD
Indomethacin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.01e-06	4.36e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3e-06	4.35e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—HRAS—urinary bladder cancer	2.99e-06	4.34e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—CREBBP—urinary bladder cancer	2.96e-06	4.29e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—ERBB2—urinary bladder cancer	2.96e-06	4.29e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.96e-06	4.28e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.96e-06	4.28e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	2.93e-06	4.24e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—PTGS2—urinary bladder cancer	2.93e-06	4.24e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—TYMS—urinary bladder cancer	2.92e-06	4.23e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—PTGS2—urinary bladder cancer	2.9e-06	4.19e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—GSTM1—urinary bladder cancer	2.89e-06	4.18e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—NCOR1—urinary bladder cancer	2.89e-06	4.18e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—IL2—urinary bladder cancer	2.88e-06	4.17e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—MYC—urinary bladder cancer	2.85e-06	4.13e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	2.81e-06	4.08e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CCND1—urinary bladder cancer	2.81e-06	4.07e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—EGFR—urinary bladder cancer	2.79e-06	4.04e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—FGFR3—urinary bladder cancer	2.79e-06	4.04e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—GPX1—urinary bladder cancer	2.76e-06	4e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.74e-06	3.96e-05	CbGpPWpGaD
Indomethacin—PPARG—Gene Expression—MYC—urinary bladder cancer	2.73e-06	3.95e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—MMP9—urinary bladder cancer	2.73e-06	3.95e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CDKN1A—urinary bladder cancer	2.72e-06	3.93e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—ERCC2—urinary bladder cancer	2.71e-06	3.93e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—PTEN—urinary bladder cancer	2.71e-06	3.92e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—EP300—urinary bladder cancer	2.7e-06	3.91e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—PTEN—urinary bladder cancer	2.7e-06	3.91e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—PTEN—urinary bladder cancer	2.7e-06	3.91e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	2.69e-06	3.9e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.67e-06	3.87e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.65e-06	3.84e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—KRAS—urinary bladder cancer	2.64e-06	3.82e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—SRC—urinary bladder cancer	2.63e-06	3.8e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—PPARG—urinary bladder cancer	2.61e-06	3.77e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—EP300—urinary bladder cancer	2.58e-06	3.74e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.58e-06	3.73e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—EP300—urinary bladder cancer	2.57e-06	3.73e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—EP300—urinary bladder cancer	2.57e-06	3.73e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—PTEN—urinary bladder cancer	2.55e-06	3.7e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—MTHFR—urinary bladder cancer	2.55e-06	3.7e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GSTP1—urinary bladder cancer	2.54e-06	3.68e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—CDKN1A—urinary bladder cancer	2.53e-06	3.67e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—PTEN—urinary bladder cancer	2.53e-06	3.66e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	2.51e-06	3.64e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	2.51e-06	3.64e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—SRC—urinary bladder cancer	2.51e-06	3.64e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—CREBBP—urinary bladder cancer	2.5e-06	3.63e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.49e-06	3.61e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.46e-06	3.56e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—EP300—urinary bladder cancer	2.43e-06	3.53e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—PTGS2—urinary bladder cancer	2.43e-06	3.51e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.42e-06	3.51e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—EP300—urinary bladder cancer	2.41e-06	3.49e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—CREBBP—urinary bladder cancer	2.37e-06	3.44e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—TYMS—urinary bladder cancer	2.36e-06	3.42e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	2.35e-06	3.4e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—TP53—urinary bladder cancer	2.34e-06	3.39e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—SRC—urinary bladder cancer	2.34e-06	3.39e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—NCOR1—urinary bladder cancer	2.34e-06	3.38e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GSTM1—urinary bladder cancer	2.34e-06	3.38e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.31e-06	3.35e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	2.3e-06	3.34e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.28e-06	3.3e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—MYC—urinary bladder cancer	2.25e-06	3.26e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—HRAS—urinary bladder cancer	2.24e-06	3.25e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—EP300—urinary bladder cancer	2.24e-06	3.25e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GPX1—urinary bladder cancer	2.24e-06	3.24e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.23e-06	3.23e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.21e-06	3.2e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—EGFR—urinary bladder cancer	2.2e-06	3.19e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—ERCC2—urinary bladder cancer	2.2e-06	3.18e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—PTEN—urinary bladder cancer	2.19e-06	3.18e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—PTEN—urinary bladder cancer	2.19e-06	3.18e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—KRAS—urinary bladder cancer	2.17e-06	3.15e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—RHOA—urinary bladder cancer	2.15e-06	3.11e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.12e-06	3.07e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—PTEN—urinary bladder cancer	2.11e-06	3.06e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.11e-06	3.06e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—MYC—urinary bladder cancer	2.1e-06	3.04e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.1e-06	3.04e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.1e-06	3.04e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—EP300—urinary bladder cancer	2.09e-06	3.03e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—EP300—urinary bladder cancer	2.09e-06	3.03e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—KRAS—urinary bladder cancer	2.08e-06	3.01e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.08e-06	3.01e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.07e-06	3e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—PPARG—urinary bladder cancer	2.07e-06	3e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—MTHFR—urinary bladder cancer	2.06e-06	2.99e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—EGFR—urinary bladder cancer	2.05e-06	2.97e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—PTGS2—urinary bladder cancer	2.05e-06	2.97e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.05e-06	2.96e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.05e-06	2.96e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—EP300—urinary bladder cancer	2.02e-06	2.92e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.01e-06	2.92e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	2.01e-06	2.91e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.01e-06	2.91e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.99e-06	2.88e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—ERBB2—urinary bladder cancer	1.99e-06	2.88e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.97e-06	2.86e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.96e-06	2.84e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—KRAS—urinary bladder cancer	1.94e-06	2.81e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.93e-06	2.8e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—TP53—urinary bladder cancer	1.93e-06	2.8e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.92e-06	2.79e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—EP300—urinary bladder cancer	1.92e-06	2.78e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.91e-06	2.77e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.91e-06	2.77e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.85e-06	2.68e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—TP53—urinary bladder cancer	1.85e-06	2.68e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—HRAS—urinary bladder cancer	1.85e-06	2.68e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.83e-06	2.65e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.81e-06	2.62e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.8e-06	2.6e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.79e-06	2.59e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—HRAS—urinary bladder cancer	1.77e-06	2.56e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—EP300—urinary bladder cancer	1.71e-06	2.47e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.7e-06	2.46e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—PTEN—urinary bladder cancer	1.69e-06	2.45e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.69e-06	2.45e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PPARG—urinary bladder cancer	1.67e-06	2.42e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—HRAS—urinary bladder cancer	1.65e-06	2.39e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—EP300—urinary bladder cancer	1.62e-06	2.34e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CREBBP—urinary bladder cancer	1.61e-06	2.33e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—SRC—urinary bladder cancer	1.57e-06	2.28e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.5e-06	2.18e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.47e-06	2.12e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.44e-06	2.09e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—PTEN—urinary bladder cancer	1.42e-06	2.06e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.41e-06	2.04e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—MYC—urinary bladder cancer	1.41e-06	2.04e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—EGFR—urinary bladder cancer	1.38e-06	2e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.37e-06	1.98e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—EP300—urinary bladder cancer	1.35e-06	1.96e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PTGS2—urinary bladder cancer	1.32e-06	1.91e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.32e-06	1.91e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—KRAS—urinary bladder cancer	1.3e-06	1.88e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.18e-06	1.71e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.15e-06	1.67e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PTEN—urinary bladder cancer	1.15e-06	1.66e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—HRAS—urinary bladder cancer	1.11e-06	1.6e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—EP300—urinary bladder cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.08e-06	1.56e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.03e-06	1.49e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.01e-06	1.46e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—EP300—urinary bladder cancer	9.83e-07	1.42e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—EP300—urinary bladder cancer	9.6e-07	1.39e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.4e-07	1.36e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—EP300—urinary bladder cancer	8.96e-07	1.3e-05	CbGpPWpGaD
